Drug Profile
Efgartigimod alfa - argenx
Alternative Names: ARGX-113; EFG PH20 SC; Efgartigimod - argenx; Efgartigimod alfa-fcab - argenx; efgartigimod PH20; efgartigimod PH20 SC; PH20 SC; VYVDURA; VYVGART; VYVGART HYTRULOLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator arGEN-X
- Developer argenx; Medison; ZAI Lab
- Class Anti-inflammatories; Antiarrhythmics; Immunoglobulin Fc fragments; Monoclonal antibodies; Skin disorder therapies; Urologics
- Mechanism of Action Neonatal Fc receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Myasthenia gravis
- Preregistration Chronic inflammatory demyelinating polyradiculoneuropathy; Idiopathic thrombocytopenic purpura
- Phase III Bullous pemphigoid; Myositis; Pemphigus
- Phase II Lupus nephritis; Membranous glomerulonephritis; Sjogren's syndrome; Tachycardia
- Preclinical Immune-mediated necrotising myopathy
Most Recent Events
- 18 Mar 2024 argenx plans a phase III trial in Graves ophthalmopathy (SC) (NCT06307626)
- 07 Mar 2024 Argenx plans phase-III trial for Myasthenia gravis (Treatment-experienced, In children, In adolescents, In adults, In the elderly) in April 2024 (IV, infusion) (NCT06298552)
- 29 Feb 2024 argenx expects regulatory approval decision on efgartigimod for Myasthenia gravis in Switzerland, Australia, Saudi Arabia and South Korea by end of 2024